Back to results
US 2023/0416249 A1Published application
N-[2-({4-[3-(anilino)-4-oxo-4,5,6,7-tetrahydro-1h-pyrrolo[3,2-c]pyridin-2-yl]pyridin-3-yl)oxy)ethyl]prop-2-enamide derivatives and similar compounds as egfr inhibitors for the treatment of cancer
AssigneesBayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
InventorsStephan SIEGEL, Franziska SIEGEL, Volker SCHULZE, Markus BERGER, Keith GRAHAM, Ulrich KLAR, Jeremie Xavier G. MORTIER, Detlev SÜLZLE, Ulf BÖMER, Daniel KORR, Jens SCHRÖDER, Matthew MEYERSON, Heidi GREULICH, Bethany KAPLAN
Life of this patent
Estimating the term…
Abstract
Compounds of formula (I) processes for their production and their use as pharmaceuticals.
Claims44
A compound of formula (I)
- in which:
- R1 represents hydrogen, methyl, ethyl, trifluoromethyl, 2,2-difluoroethyl, cyano, chloro,
- bromo, methoxy, or difluoromethoxy;
- R2 represents hydrogen, methyl, ethyl, fluoro, chloro, or bromo;
- R3 represents hydrogen or fluoro;
- R4 represents hydrogen, methyl, or trifluoromethyl;
- R5 represents hydrogen, methyl, or trifluoromethyl, or
- R4 and R5, together with the carbon atom to which they are attached, represent a C3-C6-cycloalkyl group;
- R6 represents a group selected from the group:
- wherein * indicates the point of attachment of said group to the oxygen atom of the compound of formula (I);
- R7 represents hydrogen or methyl;
- or an N-oxide, a salt or a tautomer of said compound, or a salt of said N-oxide or tautomer.
9 more elements
Dependencies are inferred from the claim text.